Surmodics, Inc. (NASDAQ:SRDX) Receives $43.00 Consensus PT from Analysts

Surmodics, Inc. (NASDAQ:SRDX) has earned a consensus recommendation of “Hold” from the five research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $43.00.

Several research firms recently weighed in on SRDX. Weiss Ratings restated a “sell (d-)” rating on shares of Surmodics in a report on Saturday, September 27th. Zacks Research upgraded Surmodics to a “hold” rating in a research note on Tuesday, August 12th. Finally, Barrington Research reissued a “market perform” rating on shares of Surmodics in a research report on Monday, August 11th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SRDX. Russell Investments Group Ltd. lifted its holdings in Surmodics by 705.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $37,000 after buying an additional 1,080 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Surmodics by 67.6% in the second quarter. BNP Paribas Financial Markets now owns 1,435 shares of the company’s stock worth $43,000 after acquiring an additional 579 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Surmodics by 289.6% in the second quarter. Tower Research Capital LLC TRC now owns 1,730 shares of the company’s stock worth $51,000 after acquiring an additional 1,286 shares in the last quarter. Strs Ohio acquired a new position in shares of Surmodics in the first quarter worth about $122,000. Finally, AlphaQuest LLC acquired a new position in shares of Surmodics in the first quarter worth about $232,000. 96.63% of the stock is owned by institutional investors and hedge funds.

Surmodics Stock Performance

NASDAQ SRDX opened at $28.82 on Friday. The firm has a market capitalization of $412.13 million, a P/E ratio of -23.43 and a beta of 1.31. Surmodics has a 1-year low of $26.00 and a 1-year high of $40.38. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.91 and a quick ratio of 3.10. The business’s 50-day simple moving average is $33.67 and its 200-day simple moving average is $30.96.

Surmodics (NASDAQ:SRDX) last released its quarterly earnings data on Friday, August 8th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.27. The business had revenue of $29.57 million for the quarter, compared to analyst estimates of $28.04 million. Surmodics had a negative return on equity of 2.99% and a negative net margin of 14.59%. Surmodics has set its FY 2025 guidance at -0.350–0.200 EPS. Equities analysts predict that Surmodics will post 0.2 EPS for the current year.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).